Streptococcus salivarius K12

Most chronic bad breath (halitosis) is not caused by food — it originates from specific bacteria colonizing the back of the tongue and producing volatile sulphur compounds (VSC): dimethyl sulphide, methyl mercaptan, hydrogen sulphide. Antiseptics temporarily suppress these bacteria but don't displace them. Streptococcus salivarius K12 works differently — it takes their place.

What It Is

Streptococcus salivarius is the dominant streptococcus of the healthy oral cavity, the first microorganism to colonize a newborn's mouth within hours of birth. Most strains of this species are harmless, but strain K12 stands out for its ability to synthesize two types of bacteriocins:

• Salivaricin A (SalA) — a lantibiotic peptide that disrupts the cell membrane of closely related bacteria
• Salivaricin B (SalB) — a second bacteriocin with a complementary activity spectrum

Both proteins belong to the BLIS (Bacteriocin-Like Inhibitory Substances) class — products developed and registered by BLIS Technologies (New Zealand), which conducted most of the clinical trials on this strain.

How It Works

The BLIS mechanism. Salivaricins A and B are ribosomally synthesized peptides targeting the peptidoglycan or membrane proteins of susceptible bacteria. The activity spectrum includes: Streptococcus pyogenes (the causative agent of strep throat), Haemophilus influenzae (otitis, bronchitis), Moraxella catarrhalis, and VSC producers — Solobacterium moorei, Atopobium parvulum, Fusobacterium spp.

Suppression of VSC producers. The main halitosis bacteria (S. moorei, anaerobic Fusobacterium) are sensitive to salivaricins. Burton et al. (2011) showed that a 3-day course of K12 lozenges reduced VSC levels by 85% in subjects with chronic halitosis, with effects persisting more than a week after the course ended.

Competitive exclusion of S. pyogenes. K12 doesn't kill streptococci immediately — it occupies receptors on the pharyngeal epithelium, physically blocking S. pyogenes adhesion. This "occupied receptor" mechanism mechanically reduces the risk of streptococcal tonsillitis.

Cross-immunity via sIgA. Sustained K12 colonisation in the throat stimulates local immune responses, increasing secretory IgA production against a broad spectrum of upper respiratory pathogens.

Efficacy

Sore throats in children (PMID: 22291583)

Di Pierro et al. (2012): 222 children with recurrent tonsillitis. K12 vs. placebo group, 90-day daily lozenge administration. Result: incidence of streptococcal pharyngitis dropped by 90% (3 episodes vs. 33 in controls), viral pharyngitis by 80%. This is one of the highest effect-size RCTs for any oral probiotic.

Large-scale RCT on 1,022 children (PMID: 26732725)

Gregori et al. (2016): confirmation at scale. The K12 group showed a 68% reduction in streptococcal tonsillitis risk and a 79% reduction in viral pharyngitis days compared to controls over a winter season (90 days).

Halitosis elimination (PMID: 20608980)

Burton et al. (2011): pilot study in 23 adults with halitosis. Outcomes: organoleptic odour score, VSC levels (halimetry), tongue microbiological composition. After a 3-day K12 course, 84% of participants achieved "good or excellent" halimetry results. K12 was detected in tongue swabs in 83% of participants 7 days post-course, confirming sustained colonisation.

Antimicrobial spectrum in vitro (PMID: 22842490)

Masdea et al. (2012) confirmed K12 inhibits 100% of tested S. pyogenes isolates and 100% of H. influenzae isolates in disc diffusion assays. In comparison, L. reuteri and other probiotic Lactobacillus species did not demonstrate this activity against these targets.

Safety

S. salivarius is a natural inhabitant of the human oral cavity. K12 lacks the virulence factors of pathogenic streptococci (S. pyogenes, S. pneumoniae): no M-protein, hyaluronidase, or streptolysin. This is a key distinction, confirmed by whole-genome sequencing.

• No transferable antibiotic-resistance genes
• Safe for children from 3 years of age (confirmed by paediatric RCTs)
• GRAS status in the USA, QPS in the EU
• No cases of bacteraemia or systemic infection reported in any trial

Role in the QDRO Formula

K12 is an ideal ingredient for an anti-halitosis QDRO line as dissolvable lozenges or a throat spray. The lozenge format provides slow release of bacteria at the back of the oral cavity — precisely where VSC producers reside.

Combined with zinc gluconate (which inhibits VSC-producing enzymes), K12 creates a two-pronged attack on halitosis: immediate zinc effect + long-term colonisation protection from the probiotic.

Brand verdict: we use it — the only probiotic with proven clinical effects on both halitosis and streptococcal tonsillitis simultaneously.

---

Sources:

• Wescombe PA et al. (2012). Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol. PMID: 22191449
• Di Pierro F et al. (2012). Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. PMID: 22291583
• Burton JP et al. (2011). A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. PMID: 20608980
• Gregori G et al. (2016). Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children: large-scale RCT. Benef Microbes. PMID: 26732725
• Masdea L et al. (2012). Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral and upper respiratory infections. New Microbiol. PMID: 22842490